NKG2D ligands as therapeutic targets
Paul Spear1, Ming-Ru Wu, Marie-Louise Sentman
1Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
Cancer Immunity
|July 9, 2013
Summary
The Natural Killer Group 2D (NKG2D) receptor targets cancer cells for immune elimination. Therapies targeting NKG2D ligands show promise for cancer treatment, with clinical trials upcoming.
Area of Science:
- Immunology
- Oncology
Background:
- The Natural Killer Group 2D (NKG2D) receptor is crucial for host defense against infections and cancer.
- NKG2D recognizes ligands expressed on stressed cells, activating lymphocytes to eliminate these cells.
- Limited expression of NKG2D ligands on healthy tissues suggests their potential as cancer immunotherapy targets.
Purpose of the Study:
- To review the role of the NKG2D receptor and its ligands in cancer, infection, and autoimmunity.
- To discuss novel immunotherapeutic strategies targeting NKG2D ligands for cancer treatment.
Main Methods:
- Literature review of studies on NKG2D receptor and ligand interactions.
- Analysis of preclinical data for therapies targeting NKG2D ligands in cancer.
- Review of ongoing and planned clinical trials.
Main Results:
- NKG2D-ligand interactions are key in immune surveillance against tumors and pathogens.
- Preclinical studies demonstrate the efficacy of targeting NKG2D ligands in various cancer models.
- Therapies targeting NKG2D ligands are advancing towards clinical application.
Conclusions:
- The NKG2D pathway represents a promising target for developing novel cancer immunotherapies.
- Targeting NKG2D ligands offers a strategy to enhance anti-tumor immunity with potential for broad applicability.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...